Dupont Capital Management’s Standard BioTools LAB Stock Holding History

Dupont Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-44,091	Closed	-$158K	–	1708
2022 Q1	$158K	Sell	44,091 -3,900	-8%	-$13.5K	0.01%	1149
2021 Q4	$188K	Buy	47,991 +7,922	+20%	+$37.1K	0.01%	1141
2021 Q3	$264K	Sell	40,069 -5,664	-12%	-$37.3K	0.01%	1118
2021 Q2	$282K	Buy	+45,733	New	+$244K	0.01%	1217
2020 Q3	–	Sell	-76,246	Closed	-$306K	–	1373
2020 Q2	$306K	Sell	76,246 -122,961	-62%	-$428K	0.01%	962
2020 Q1	$506K	Hold	199,207	–	–	0.01%	657
2019 Q4	$693K	Buy	199,207 +138,527	+228%	+$487K	0.02%	694
2019 Q3	$281K	Buy	60,680 +14,690	+32%	+$116K	0.01%	1027
2019 Q2	$567K	Buy	+45,990	New	+$586K	0.01%	722

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dupont Capital Management's LAB Position: Q2 2022 in Review

Dupont Capital Management sold out of Standard BioTools (LAB) in Q2 2022, closing a stake of 44,091 shares — an estimated $158K sold.

Dupont Capital Management first reported a position in LAB in Q2 2019 and held it in 9 quarters. The position peaked at $693K in Q4 2019. 86 funds tracked by Wall St. Rank hold LAB as of Q2 2022.

Dupont Capital Management reported no remaining Standard BioTools position as of Q2 2022 after selling out during the quarter.
Dupont Capital Management sold 44,091 Standard BioTools shares in Q2 2022, an estimated $158K.
Dupont Capital Management first reported a position in Standard BioTools in Q2 2019 and held it in 9 quarters.
Dupont Capital Management's Standard BioTools position peaked at $693K in Q4 2019.
86 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2022.

Based on Dupont Capital Management's 13F filing for Q2 2022, filed 26 Jul 2022.